Karyopharm Therapeutics Inc
Nasdaq KPTI · Newton, MA
Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Karyopharm Therapeutics Inc is a clinical trial sponsor based in Newton, MA, listed as Nasdaq KPTI. It has 8 active clinical trials with 1,952 planned participants, across 13 therapeutic areas. Since 2021 it has completed 12 trials and stopped 16 early.
Trial track record · since 2021
Financials · Nasdaq KPTI
Pipeline · 8 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
1 approved drug application with a product on the market.
Questions about Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc is lead sponsor of 8 active clinical trials on ClinicalTrials.gov, with 1,952 planned participants, in Cardiovascular, Dermatology, GI & liver, Hematology and other areas. Since 2021 it has completed 12 trials and stopped 16 early.
Karyopharm Therapeutics Inc is based in Newton, MA and is listed as Nasdaq KPTI. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Karyopharm Therapeutics Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-09.
Approve Suite is not affiliated with Karyopharm Therapeutics Inc.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.